The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
FoxO3 Transcription Factor and Sirt6 Deacetylase Regulate Low Density Lipoprotein (LDL)-cholesterol Homeostasis via Control of the Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Gene Expression
Open accessAbstract
Elevated LDL-cholesterol is a risk factor for the development of cardiovascular disease. Thus, proper control of LDL-cholesterol homeostasis is critical for organismal health. Genetic analysis has identified PCSK9 (proprotein convertase subtilisin/kexin type 9) as a crucial gene in the regulation of LDL-cholesterol via control of LDL receptor degradation. Although biochemical characteristics and clinical implications of PCSK9 have been extensively investigated, epigenetic regulation of this gene is largely unknown. In this work we have discovered that Sirt6, an NAD + -dependent histone deacetylase, plays a critical role in the regulation of the Pcsk9 gene expression in mice. Hepatic Sirt6 deficiency leads to elevated Pcsk9 gene expression and LDL-cholesterol as well. Mechanistically, we have demonstrated that Sirt6 can be recruited by forkhead transcription factor FoxO3 to the proximal promoter region of the Pcsk9 gene and deacetylates histone H3 at lysines 9 and 56, thereby suppressing the gene expression. Also remarkably, overexpression of Sirt6 in high fat diet-fed mice lowers LDL-cholesterol. Overall, our data suggest that FoxO3 and Sirt6, two longevity genes, can reduce LDL-cholesterol levels through regulation of the Pcsk9 gene. Background: PCSK9 is critical for LDL-cholesterol regulation, but the epigenetic regulation of the PCSK9 gene is not clear. Results: FoxO3 and Sirt6 suppress the PCSK9 gene expression and reduce LDL-cholesterol. Conclusion: Hepatic FoxO3 and Sirt6 control LDL-cholesterol homeostasis. Significance: FoxO3 and Sirt6 are important for cardiovascular health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhao, J., Brault, J. J., Schild, A., Cao, P., Sandri, M., Schiaffino, S., Lecker, S. H., & Goldberg, A. L. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.004 · Cited by 1,489 · cited 1×
“Adenoviruses for SIRT6 and FOXO3 overexpression were generated as previously described (39, 42).”
MethodSIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin
Michishita, E., McCord, R. A., Berber, E., Kioi, M., Padilla-Nash, H., Damian, M., Cheung, P., Kusumoto, R., Kawahara, T. L. A., Barrett, J. C., et al. (2008) · Nature · doi:10.1038/nature06736 · Cited by 1,111
The sirtuin SIRT6 regulates lifespan in male mice
Kanfi, Y., Naiman, S., Amir, G., Peshti, V., Zinman, G., Nahum, L., Bar-Joseph, Z., & Cohen, H. Y. (2012) · Nature · doi:10.1038/nature10815 · Cited by 1,059
FOXO3A genotype is strongly associated with human longevity
Willcox, B. J., Donlon, T. A., He, Q., Chen, R., Grove, J. S., Yano, K., Masaki, K. H., Willcox, D. C., Rodriguez, B., & Curb, J. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801030105 · Cited by 983
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice
Lagace, T. A., Curtis, D. E., Garuti, R., McNutt, M. C., Park, S. W., Prather, H. B., Anderson, N. N., Ho, Y. K., Hammer, R. E., & Horton, J. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29383 · Cited by 681
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Stein, E. A., Mellis, S., Yancopoulos, G. D., Stahl, N., Logan, D., Smith, W. B., Lisbon, E., Gutierrez, M., Webb, C., Wu, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105803 · Cited by 664
Association of FOXO3A variation with human longevity confirmed in German centenarians
Flachsbart, F., Caliebe, A., Kleindorp, R., Blanché, H., von Eller-Eberstein, H., Nikolaus, S., Schreiber, S., & Nebel, A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809594106 · Cited by 572
(2010) · doi:10.1016/j.cmet.2010.06.009 · Cited by 512
Self-citationDong, X. C., Copps, K. D., Guo, S., Li, Y., Kollipara, R., DePinho, R. A., & White, M. F. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.06.006 · Cited by 463 · cited 1×
“Blood samples were collected and analyzed as previously described (41).”
MethodSelf-citationSullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.25790 · Cited by 447
Cited by
Mechanisms and regulation of cholesterol homeostasis
Luo, J., Yang, H., & Song, B.-L. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0190-7 · Cited by 1,980
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
“In addition, PPARγ increases the PCSK9 gene expression in the liver,(204) while peroxisome proliferator-activated receptor-α (PPARα),(205) SIRT1, and SIRT6 decrease its expression.(206) Pro-PCSK9 includes five domains: a signal peptide (aa 1–30), an N-terminal prodomain (aa 31–152) that is cleaved in the ER, a catalyt…”
BackgroundRedox regulation of FoxO transcription factors
Klotz, L.-O., Sánchez-Ramos, C., Prieto-Arroyo, I., Urbánek, P., Steinbrenner, H., & Monsalve, M. (2015) · Redox Biology · doi:10.1016/j.redox.2015.06.019 · Cited by 747
“Sirt6 was shown to affect FoxO3a-dependent transcription of SREBP2 (sterol-regulatory element binding protein 2), a major transcriptional regulator of cholesterol biosynthesis, and PCSK9 (proprotein convertase subtilisin/kexin type 9), a crucial enzyme for the control of LDL receptor degradation: FoxO3a recruits Sirt6…”
BackgroundSeidah (2014) · doi:10.1161/circresaha.114.301621 · Cited by 596
Sirtuins and NAD + in the Development and Treatment of Metabolic and Cardiovascular Diseases
Kane, A. E., & Sinclair, D. A. (2018) · Circulation Research · doi:10.1161/circresaha.118.312498 · Cited by 487
Protective effects of sirtuins in cardiovascular diseases: from bench to bedside
Winnik, S., Auwerx, J., Sinclair, D. A., & Matter, C. M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv290 · Cited by 422
Chromatin and beyond: the multitasking roles for SIRT6
Kugel, S., & Mostoslavsky, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.002 · Cited by 367
FOXO3: A Major Gene for Human Longevity - A Mini-Review
Morris, B. J., Willcox, D. C., Donlon, T. A., & Willcox, B. J. (2015) · Gerontology · doi:10.1159/000375235 · Cited by 353
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Wu, X., Xu, M., Geng, M., Chen, S., Little, P. J., Xu, S., & Weng, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01439-y · Cited by 272
Sirtuins in Epigenetic Regulation
Jing, H., & Lin, H. (2015) · Chemical Reviews · doi:10.1021/cr500457h · Cited by 270
SIRT6: Novel Mechanisms and Links to Aging and Disease
Tasselli, L., Zheng, W., & Chua, K. F. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.002 · Cited by 265
Sirtuins, Cell Senescence, and Vascular Aging
Kida, Y., & Goligorsky, M. S. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.11.022 · Cited by 256
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
Schulz, R., Schlüter, K.-D., & Laufs, U. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0463-z · Cited by 137
Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Xia, X.-D., Peng, Z.-S., Gu, H.-M., Wang, M., Wang, G.-Q., & Zhang, D.-W. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.764038 · Cited by 125
Wong, C. C., Wu, J.-L., Ji, F., Kang, W., Bian, X., Chen, H., Chan, L.-S., Luk, S. T. Y., Tong, S., Xu, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31663-z · Cited by 103
Tao, R., Xiong, X., Liangpunsakul, S., & Dong, X. C. (2015) · Diabetes · doi:10.2337/db14-0539 · Cited by 96
Self-citationPCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sundararaman, S. S., Döring, Y., & van der Vorst, E. P. C. (2021) · Biomedicines · doi:10.3390/biomedicines9070793 · Cited by 67
Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol
Spolitu, S., Okamoto, H., Dai, W., Zadroga, J. A., Wittchen, E. S., Gromada, J., & Ozcan, L. (2019) · Circulation Research · doi:10.1161/circresaha.118.313648 · Cited by 64
Sirtuin 6—A Key Regulator of Hepatic Lipid Metabolism and Liver Health
Dong, X. C. (2023) · Cells · doi:10.3390/cells12040663 · Cited by 63
Self-citationPCSK9 in metabolism and diseases
Ajoolabady, A., Pratico, D., Mazidi, M., Davies, I. G., Lip, G. Y. H., Seidah, N., Libby, P., Kroemer, G., & Ren, J. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156064 · Cited by 49
Wang, Y., Zhang, L., Lv, L., Zhou, Z., & Xi, H. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23346 · Cited by 10
Metadata
- Authors
- Tao, R., Xiong, X., DePinho, R. A., Deng, C.-X., & Dong, X. C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 288
- Issue
- 41
- Pages
- 29252-29259
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2078340601
- Cited by
- 193
- References
- 12
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.